CA2205600A1 - Compositions d'ondansetron lyophilisees - Google Patents

Compositions d'ondansetron lyophilisees

Info

Publication number: CA2205600A1
Authority: CA; Canada
Prior art keywords: freeze; compositions; dried; pharmaceutically acceptable; ondansetron compositions
Prior art date: 1994-11-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA 2205600

Other languages

English (en)

Other versions

CA2205600C (fr

Inventor

Ian Keith Winterborn

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-22

Filing date

1995-11-20

Publication date

1996-05-30

1994-11-22 Priority claimed from GB9423511A external-priority patent/GB9423511D0/en

1995-11-20 Application filed by Individual filed Critical Individual

1996-05-30 Publication of CA2205600A1 publication Critical patent/CA2205600A1/fr

2000-05-30 Application granted granted Critical

2000-05-30 Publication of CA2205600C publication Critical patent/CA2205600C/fr

2015-11-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
229960005343 ondansetron Drugs 0.000 title abstract 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 4
102000035037 5-HT3 receptors Human genes 0.000 abstract 1
108091005477 5-HT3 receptors Proteins 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
239000012458 free base Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Landscapes

Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 2205600 1994-11-22 1995-11-20 Compositions d'ondansetron lyophilisees Expired - Lifetime CA2205600C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9423511A GB9423511D0 (en)	1994-11-22	1994-11-22	Compositions
GB9423511.6		1994-11-22
PCT/EP1995/004550 WO1996015785A1 (fr)	1994-11-22	1995-11-20	Compositions d'ondansetron lyophilisees

Publications (2)

Publication Number	Publication Date
CA2205600A1 true CA2205600A1 (fr)	1996-05-30
CA2205600C CA2205600C (fr)	2000-05-30

Family

ID=29421792

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2205600 Expired - Lifetime CA2205600C (fr)	1994-11-22	1995-11-20	Compositions d'ondansetron lyophilisees

Country Status (1)

Country	Link
CA (1)	CA2205600C (fr)

1995
- 1995-11-20 CA CA 2205600 patent/CA2205600C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2205600C (fr)	2000-05-30

Legal Events

Date	Code	Title	Description
1998-09-03	EEER	Examination request
2016-01-24	MKEX	Expiry	Effective date: 20151120

Publication	Publication Date	Title
GB2295318B (en)	1998-10-28	Freeze-dried dosage form containing ondansetron
CA2205546A1 (fr)	1996-05-30	Compositions orales contenant de l'ondansetron
AP1637A (en)	2006-07-17	Celecoxib compositions.
CA2362816A1 (fr)	2001-06-14	Compositions de valdecoxib
CA2180178A1 (fr)	1995-07-06	Utilisation des derives 2,3-diaryl-1-benzopyrane dans la production d'un medicament employe dans le traitement et la prevention de la diminution du volume du tissu osseux et de l'osteoporose
CA2135179A1 (fr)	1993-11-11	Compositions pharmaceutiques d'agonistes 5ht1 de type alkylsulfonamides, pour administration rectale
CA2205600A1 (fr)	1996-05-30	Compositions d'ondansetron lyophilisees
CA2162919A1 (fr)	1994-12-08	Compositions pour administration rectale
WO2002055062A3 (fr)	2003-03-13	Comprime pharmaceutique comprenant du mesylate de paroxetine